ONK Therapeutics is dedicated to optimizing a next generation of off-the-shelf, dual-targeted NK cell therapies for patients with hematological malignancies and solid tumors.
Harnessing the innate biology of NK cells
The company’s unique approach harnesses the innate biology of NK cells, which are optimized through its proprietary platform, introducing genetic modifications to improve both functionality and cytotoxicity.
The company’s proprietary NK cell therapy platform is based on a dual-targeted construct, combining a chimeric antigen receptor (CAR) targeting a known tumor antigen, with a TRAIL variant targeting the death receptor pathway through DR4 or DR5. This dual-targeted approach has the potential to improve efficacy and be less vulnerable to antigen escape.
This platform could be broadly applicable across a wide range of targets and tumor types, with the potential to bring significant therapeutic benefit.
ONK Therapeutics is a privately held company, founded in 2015 based on the NK cell and apoptosis research of its founder Prof M O’Dwyer. MD and collaborators at National University of Ireland, Galway.